Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: A novel analysis

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2267-2271

  Leibman, Bryan D ^a   Dillioglugil, Ozdal ^a   Scardino, Peter T ^a   Abbas, Farhat ^a   Rogers, Eamonn ^a   Wolfinger, Russell D ^a   Kattan, Michael W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR GROWTH;

EID: 0031747706     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2267     Document Type: Article

References (18)

1. Stamey TA, Kabalin JN, McNeal JE, et al: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 141:1076-1083, 1989
2. Trapasso JG, deKernion JB, Smith RB, et al: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152:1821-1825, 1994
3. Partin AW, Pearson JD, Landis PK, et al: Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43:649-659, 1994
4. Hanks GE, D'Amico A, Epstein BE, et al: Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys 27:125-127, 1993
5. Zagars GK, Pollack AP: Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome. Urology 45:476-483, 1995
6. Pollack AP, Zagars GK, Kavadi VS: Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74:670-678, 1994
7. D'Amico AV, Hanks GE: Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 72:2638-2643, 1993
8. Beahrs OH, Henson DE, Hutter RV, et al (eds): Manual for Staging of Cancer. Philadelphia, PA, Lippincott, 1992
9. Butler EB, Scardino PT, The BS, et al: The Baylor College of Medicine experience with gold seed implantation. Semin Surg Oncol 13:406-418, 1997
10. Ohori M, Wheeler TM, Scardino PT: The new American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer: Clinicopathologic correlations. Cancer 74:104-114, 1994
11. Littell RC, Milliken GA, Stroup WW, et al: SAS System for Mixed Models. Cary, NC, SAS Institute, 1996
12. Diggle PJ, Liang KY, Zeger SL: Analysis of Longitudinal Data. Oxford, United Kingdom, Clarendon, 1994
13. Wang MC, Valenzuela LA, Murphy GP, et al: Purification of a human prostate specific antigen. Invest Urol 17:159-163, 1979
14. Gann PH, Hennekens CH, Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 273:289-294, 1995
15. Frazier HA, Robertson JE, Humphrey PA, et al: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 149:516-518, 1993
16. Schmid H, McNeal JE, Stamey TA: Observations on the doubling time of prostate cancer. Cancer 71:2031-2040, 1993
17. Stamey TA, Ferrari MK, Schmid H-P: The value of serial prostate specific antigen determinations 5 years after radiotherapy: Steeply increasing values characterize 80% of patients. J Urol 150:1856-1859, 1993
18. Fowler JE, Pandey P, Braswell NT, et al: Prostate specific antigen progression rates after radical prostatectomy or radiation for localized prostate cancer. Surgery 116:302-306, 1994